Worsening after rituximab treatment in anti-mag neuropathy

Muscle Nerve. 2005 Sep;32(3):378-9. doi: 10.1002/mus.20386.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / immunology
  • B-Lymphocytes / drug effects
  • B-Lymphocytes / immunology
  • Disease Progression
  • Female
  • Humans
  • Immunoglobulin M / blood
  • Immunoglobulin M / immunology
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / adverse effects
  • Immunosuppression Therapy / adverse effects
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology
  • Muscle Weakness / drug therapy
  • Muscle Weakness / immunology
  • Muscle Weakness / physiopathology
  • Myelin-Associated Glycoprotein / immunology*
  • Polyneuropathies / drug therapy*
  • Polyneuropathies / immunology
  • Polyneuropathies / physiopathology
  • Polyradiculoneuropathy / drug therapy*
  • Polyradiculoneuropathy / immunology
  • Polyradiculoneuropathy / physiopathology
  • Rituximab
  • Treatment Failure

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Immunoglobulin M
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Myelin-Associated Glycoprotein
  • Rituximab